Another phase II study enrolled 12 patients with R/R PTCL—including six with AITL, three with PTCL-NOS, and one with ALK− ALCL—half of whom had received ASCT. The gene discussed is ALK; the disease is mature T-cell and NK-cell non-Hodgkin lymphoma.